Safety of Abrocitinib in 3582 Patients With Moderate-to-Severe Atopic Dermatitis With Over 900 Patients Exposed for Almost 2 Years

Main Article Content

Eric L. Simpson
Johnathan Silverberg
Audrey Nosbaum
Kevin Winthrop
Emma Guttman-Yassky
Karin M. Hoffmeister
Alexander Egeberg
Hernan Valdez
Haiyun Fan
Saleem A. Farooqui
Gary L. Chan
Justine Alderfer
William Romero
Susan Johnson

Keywords

Abrocitinib, JAK1 inhibitor, moderate-to-severe atopic dermatitis, Long-Term Safety, JADE EXTEND

References

1. Cibinqo (abrocitinib). Summary of product characteristics. European Medicines Agency; December 17, 2021.

2. Cibinqo (abrocitinib) tablets. Prescribing information. Pfizer Labs; January 2022.

3. Cibinqo (abrocitinib), 100 mg film-coated tablets. Summary of product characteristics. Pfizer Ltd.; September 10, 2021.

4. Simpson EL et al. Am J Clin Dermatol. 2021;22:693-707.

5. Cork MJ et al. Presented at: European Academy of Dermatology and Venereology (EADV) Congress; September 29-October 2, 2021; Berlin, Germany.

Article Sidebar

Poster PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.150

Article Details

How to Cite
[1]
Simpson, E.L. , Silverberg, J., Nosbaum, A., Winthrop, K., Guttman-Yassky, E., Hoffmeister, K.M., Egeberg, A., Valdez, H., Fan, H., Farooqui, S.A., Chan, G.L., Alderfer, J., Romero, W. and Johnson, S. 2023. Safety of Abrocitinib in 3582 Patients With Moderate-to-Severe Atopic Dermatitis With Over 900 Patients Exposed for Almost 2 Years. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s150. DOI:https://doi.org/10.25251/skin.7.supp.150.
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 > >>